

The TAIHO Group's Contribution to the SDGs



Under the corporate philosophy of "We strive to improve human health and contribute to a society enriched by smiles," the TAIHO Group considers Sustainable Development Goal 3, "Ensure healthy lives and promote well-being for all at all ages," to be the most important item. The Group has been working to contribute to its achievement through the Group's business activities.

Satisfying unmet medical needs by strengthening versatile drug discovery capabilities

The TAIHO Group aims to enhance human health through research and development of pharmaceuticals that can address unmet medical needs and other unique products that can be used to provide consumer-centered support as well as by offering enhanced access to these products globally. Our initiatives support SDG 3.4¹. Specifically, we are undertaking the following initiatives.

● Contributions to cancer treatment

- In order to address unmet medical needs for cancer patients around the world, the TAIHO Group is committed to in-house drug discovery and development of anticancer drugs. While improving and expanding platform technologies for drug discovery, we develop our own technologies through collaboration with research facilities inside and outside Japan in order to increase the speed of R&D. By sharing expertise and cutting-edge technologies in collaboration and alliances with the Otsuka Group and other companies, we work to strengthen our drug discovery capabilities, to further improve our development capabilities, and to accelerate global expansion. We also access unique, innovative technologies and drug discovery seeds not available within the company by building a network with domestic and foreign promising bio ventures and academia groups through investment to the TAIHO Group's corporate venture capitalist TAIHO VENTURES, LLC, Taiho Innovations, LLC, and the open innovation fund Remiges BioPharma Fund, LP. All of these efforts are structured to contribute to the health of patients around the world and to bring smiles to them. While endeavoring to achieve innovation through in-house drug discovery and various collaborations, we take on the challenge of research and development of innovative new pharmaceuticals.

- The TAIHO Group strives to provide total support for cancer treatment. To this end, the Group engages in fair marketing activities all over the world in order to suggest treatments based on anticancer drugs developed in-house, such as TS-1 and Lonsurf, while focusing its efforts within Japan on alleviating the pain caused by cancer and the side effects associated with treatment using anticancer drugs, including nausea and vomiting. The Group also plans and holds seminars as well as prepare product information materials, such as brochures and website contents, in collaboration with related internal divisions in an attempt to communicate product information and to deliver information on proper use to health care workers in a scientific and fair manner.

¹ Target 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Meeting medical needs related to cancer patients by improving access to information and treatment

The TAIHO Group is striving to improve cancer patients' access to healthcare by supporting Non-Profit Organizations and patient groups, disseminating health information and providing high quality information. Okayama Taiho Pharmaceutical Co., Ltd. is working to provide support for cancer treatment at a more appropriate cost by manufacturing and selling safe, effective, high quality authorized generics*. Our initiatives support SDG 3.8². Specifically, we are undertaking the following initiatives.

●Providing information that meets the needs of cancer patients, not just therapeutic information

- The TAIHO Group provides information that meets the needs of cancer patients, including information related to cancer treatment, by publishing through the websites and providing information materials. Some of these are shown below.

The Group also endeavors to improve access for cancer patients (and their family members) to cancer treatment and related information through partnerships with NPOs, patient groups, public organizations, and so on.

"20—TWENTY—": This booklet has been created for those who will undergo cancer treatment who are mainly of the adolescent and young adult (AYA) generation (those in their 10s and 20s), their family members, friends, and others who are living with them. It provides tips on how to take care of one's skin, wear wigs, and cope with other appearance-related problems as well as how to generate a positive mood and how to solve issues in daily life that one must overcome.

"Fertility Preservation Handbook for Cancer Patients: Thinking about having a child": We hope that through this booklet, patients will be able to learn about fertility preservation before starting cancer treatment in order to understand that there is hope for individual patients to have children in the future so that they can undergo treatment based on such an understanding. *Fertility: "ease of conception" or "strength to conceive"



- TAIHO ONCOLOGY, INC. is highly regarded in oncology for our strong support and engagement of patient advocacy organizations and provides funding support for patient and caregiver programs, initiatives, education and research. Taiho has been making it possible, every year, for colorectal cancer patients and their caregivers to access important information related to disease screening, early detection, and potential treatments by supporting the Undy RunWalk event series for six consecutive years (now known as the Walk to End Colon Cancer), COLONTOWN[®] National Empowering Patient Leaders WorkshopsSM, and Climb for a Cure through sponsorships with the Colorectal Cancer Alliance, PALTOWN, and Fight Colorectal Cancer. With our launch into gastric cancer, Taiho Oncology has expanded our engagement and support to several gastric cancer advocacy patient organizations, including Debbie's Dream Foundation, Gastric Cancer Foundation, Hope for Stomach Cancer and No Stomach For Cancer. Additionally, Taiho has continued this commitment to cancer patient organizations with Myelodysplastic Syndrome and cholangiocarcinoma-related foundations.

² Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.

- TAIHO ONCOLOGY, INC. implements a patient support program (Taiho Oncology Patient Support™) to provide services (e.g., insurance verification, treatment payment aid, and support for treatment planning) to patients, caregivers, and healthcare workers upon starting treatment with Lonsurf.



- TAIHO PHARMA CANADA, INC. implements a personalized patient support program (Conexus Patient Support Program™) to provide services including reimbursement navigation, dedicated one-on-one nurse support, specialty pharmacy services and home delivery, and educational services to patients, caregivers, and healthcare workers upon starting treatment with Lonsurf.



● Improving access to cancer treatment

- Okayama Taiho Pharmaceutical manufactures and sells authorized generics for antimetabolites released and licensed by Taiho Pharmaceutical so that many more people can use such drugs. By continuing to stably supply drugs that have long been used due to their reliability in the form of authorized generics as well as by continuing to provide quality and safety information into the future, Okayama Taiho and the TAIHO Group contribute to realizing a society in which everyone can obtain medical care with a sense of security.

*Authorized generics: A generic drug licensed under a patent, etc. by the manufacturer of the original drug which is identical to the original drug in terms of its active pharmaceutical ingredients, additives, manufacturing method, and so on. An authorized generic can be marketed before the patent for the original drug expires, which facilitates faster delivery to patients than is possible with general generic drugs. As authorized generic is an instance of generic drugs, they are less costly than the original drugs.

- TAIHO PHARMA SINGAPORE PTE. LTD. has been working to improve access to standard therapeutic agents such as TS-1 and Lonsurf, which are recommended in the Pan-Asian adapted ESMO Clinical Practice Guidelines, by expanding its direct selling structure in ASEAN countries through business.

● Expanding access to investigational drugs for cancer: implementation of the "Expanded Access Program"

- TAIHO ONCOLOGY, INC. enables cancer patients to access investigational drugs through the Expanded Access Program. Although it is desirable to offer all cancer patients who wish to participate in a clinical trial an opportunity to do so, that is not always possible. In such cases, TAIHO ONCOLOGY accepts requests for prior approval to use of investigational drugs from clinicians through the Expanded Access Program, which enables patients who have a serious life-threatening illness with no viable options to access investigational drugs.

● Improving access to unapproved drugs: "Named Based Patient Program"

- From a humanist perspective as well as the viewpoint of proper use, TAIHO PHARMA SINGAPORE PTE. LTD. enables access to unapproved drugs for patients with high medical needs through the Named Based Patient Program.



As a member of the Otsuka Group, Taiho Pharmaceutical has signed the Women's Empowerment Principles (WEPs) and provides education to its directors, executive officers, and management-level employees. Under an initiative carried out in cooperation with the TAIHO Group, Taiho Pharmaceutical has established a telecommuting program for an extended period (Family Smile Support Work Regulations) for employees to provide nursing care and childcare as well as to take care of family members with illnesses. Also, in 2019, Taiho Pharmaceutical joined the Ikuboss Project (a company alliance advocated by the NPO Fathering Japan) and strives to promote participation in housework and childcare activities among male employees as well as to develop leaders who can give considerations to work-life balance, which can be said to be the twin pillars of women's success.

At Taiho Pharmaceutical, the percentage of female managers in managerial positions is 12% in 2020 (the percentage of female employees is 24%). As an effort toward the continued development of female managers, the company dispatches female employees to empowerment programs held inside and outside Japan. In addition, the company has been taking steps to respond to diversifying work environments by promoting online training for each level of employees (this was previously conducted as group setting) and taking other actions.


Since 2017, the company has been certified by Platinum Kurumin as a Good Supporter of Child-rearing since 2017. The working group to promote women's participation in the workplace, which has promoted the introduction of telecommuting and flextime work systems, activities to install child safety seats in commercial vehicles, interviews and forums on taking maternity leave return, seminars on caregiving, and creation of a nursing care guidebook, was upgraded to the Diversity 2.0 working group in 2020 and continues to engage in more diversified activities.



Taiho Pharmaceutical and Okayama Taiho Pharmaceutical have been working to achieve efficient use of water resources by setting a target for effective use of water resources. To reduce the environmental burden on water areas, the companies also give consideration to manufacturing processes. In addition, Taiho Pharmaceutical and Okayama Taiho Pharmaceutical have installed a biotope for the preservation of biodiversity.

[Target]

- Improve water-use efficiency by 15% by 2030 comparing to the 2017 levels



As a pioneer in the development of oral anticancer agents, Taiho Pharmaceutical has established a system and developed an environment to provide a workplace where employees can continue to work even while undergoing treatment for cancer or other diseases, and the company provides education on this system. The company has strengthened its initiatives for health management and provides health support, such as support for workers with cancer, health management hours, and smoking cessation. In addition, by promoting diverse work styles, such as a flextime work system and remote work, the company is working to establish a system that enables employees to work in a style that suits them and maintain balance between work and growth (learning) as well as life.

Taiho Pharmaceutical was recognized under the Certified Health & Productivity Management Outstanding Organizations Recognition Program's WHITE500 that is chosen jointly by the Ministry of Economy, Trade, and Industry and Nippon Kenko Kaigi in 2018 and 2019, and recognized again under the 2020 certified organization.



Taiho Pharmaceutical has developed a group-wide procurement policy that takes into account human rights, labor, the environment, corruption prevention, and other topics. The company shares this policy with its business and is aware of the current situation with regard to partners' human rights, labor, and other topics through questionnaire surveys.

The company has established a Diversity 2.0 working group and started to consider LGBT and other initiatives. Taiho Pharmaceutical distributes a weekly micro-learning program in which all employees participate that aims to achieve harassment-free workplaces and organizational culture reform.



To realize a recycling-oriented society, Taiho Pharmaceutical has set the following target regarding waste. In order to attain this target, the company promotes the 3Rs (Reduce, Reuse, Recycle) initiative. In addition, as a pharmaceutical manufacturer, Taiho Pharmaceutical implements appropriate management of chemical substances, such as reduction of chemical substances released to the atmosphere through the use of a solvent recovery equipment and sophisticated management of chemical substances by system implementation.

[Target]

- Reduce the amount of simple incineration and landfilling by 50% by 2030 comparing to the 2019 levels



Taiho Pharmaceutical has set the following greenhouse gas (GHG) reduction targets. These targets are consistent with the scientific basis for achieving the goals of the Paris Agreement and certified by the Science Based Targets (SBT), an international initiative. In order to attain these targets, Taiho Pharmaceutical is taking steps such as purchasing CO₂-free electricity and introducing renewable energy such as solar power generation.

[Targets]

- Reduce GHG emissions (Scopes 1 and 2) by 30% by 2030 comparing to the 2017 levels
- Reduce GHG emissions (Scope 3) by 20% by 2030 comparing to the 2017 levels

Scope 1: Direct emissions from in-house fuel use and industrial processes

Scope 2: Indirect energy-derived emissions from the use of electricity and heat purchased by the company

Scope 3: Other indirect emissions



Under the corporate philosophy of "We strive to improve human health and contribute to a society enriched by smiles," Taiho Pharmaceutical is engaged in the business of providing pharmaceuticals that are useful for overcoming diseases as

well as maintaining and improving people's healthy lives. In its business activities, Taiho Pharmaceutical adheres to its compliance program as well as related laws, regulations, and rules while striving to become a valuable company that is trusted by society.



In order to deliver new drugs to patients as soon as possible, the TAIHO Group has been working to implement Japan-based drug discovery as well as global open innovation projects through collaboration and alliances with research institutions inside and outside Japan, promising bio ventures and academia groups, the Otsuka Group, and other companies. The TAIHO Group strives to improve access for cancer patients and their family members to required information on cancer treatment and other related information through partnerships with NPOs, patient groups, public organizations, and other parties.